/COLL
COLL Stock - Collegium Pharmaceutical, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$48.88-0.91%
$0.45 (-0.91%) • Dec 19
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.99
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).87
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.96
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+18.7%upside
Target: $58.02
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for COLL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$48.39 – $49.37
TARGET (TP)$58.00
STOP LOSS$44.97
RISK/REWARD1:2.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.61
52W High$49.92
52W Low$23.23
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $631.45M | $566.77M | $463.93M | $276.87M | $310.02M |
| Gross Profit | $377.34M | $326.17M | $209.49M | $150.62M | $179.84M |
| Gross Margin | 59.8% | 57.5% | 45.2% | 54.4% | 58.0% |
| Operating Income | $169.90M | $166.96M | $33.32M | $17.63M | $56.23M |
| Net Income | $69.19M | $48.16M | $-25,002,000 | $71.52M | $26.75M |
| Net Margin | 11.0% | 8.5% | -5.4% | 25.8% | 8.6% |
| EPS | $2.14 | $1.60 | $-0.74 | $2.05 | $0.78 |
Company Overview
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
56%
Hold / Neutral
4
44%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
5 Bullish4 Neutral/Bearish
Price Targets
$42
Average Target
↓ 13.8% Downside
Now
$30
Low
$42
Average
$58
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $58 |
| January 10th 2025 | Needham | Upgrade | Buy | $46 |
| July 30th 2024 | H.C. Wainwright | Upgrade | Buy | $47 |
| June 7th 2024 | Jefferies | Upgrade | Buy | $44← $41 |
| May 10th 2024 | Needham | Downgrade | Hold | - |
| May 10th 2024 | Piper Sandler | Downgrade | Neutral | $39 |
| January 4th 2024 | Jefferies | Downgrade | Hold | $37← $30 |
| August 25th 2023 | Needham | Reiterated | Buy | $36← $35 |
| May 2nd 2023 | Jefferies | Resumed | Buy | $30 |
| August 8th 2022 | H.C. Wainwright | Downgrade | Neutral | - |
Earnings History & Surprises
COLLBeat Rate
47%
Last 17 quarters
Avg Surprise
-19.6%
EPS vs Estimate
Beats / Misses
8/8
1 met exactly
Latest EPS
$2.25
Q4 2025
EPS Surprise History
Q4 23
+8.1%
$1.34vs$1.24
Q1 24
+18.8%
$1.58vs$1.33
Q2 24
-2.7%
$1.45vs$1.49
Q3 24
+3.8%
$1.62vs$1.56
Q4 24
-3.0%
$1.61vs$1.66
Q1 25
+14.9%
$1.77vs$1.54
Q2 25
+4.2%
$1.49vs$1.43
Q4 25
+19.7%
$2.25vs$1.88
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $2.21 | — | — | — |
Q4 2025 | Nov 6, 2025 | $1.88 | $2.25 | +19.7% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $1.62 | — | — | — |
Q2 2025 | May 8, 2025 | $1.43 | $1.49 | +4.2% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $1.54 | $1.77 | +14.9% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $1.66 | $1.61 | -3.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $1.56 | $1.62 | +3.8% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $1.49 | $1.45 | -2.7% | ✗ MISS |
Q1 2024 | Feb 22, 2024 | $1.33 | $1.58 | +18.8% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $1.24 | $1.34 | +8.1% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $1.22 | $1.26 | +3.3% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $1.32 | $1.32 | 0.0% | = MET |
Q1 2023 | Feb 23, 2023 | $1.03 | $1.09 | +5.8% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $1.22 | $1.10 | -9.8% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $1.31 | $0.13 | -90.1% | ✗ MISS |
Q2 2022 | May 10, 2022 | $0.97 | $0.60 | -38.1% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $1.04 | $-0.73 | -170.2% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $0.95 | $0.22 | -76.8% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $0.34 | $0.27 | -20.6% | ✗ MISS |
Latest News
Barclays Initiates Coverage On Collegium Pharmaceutical with Overweight Rating, Announces Price Target of $58
📈 PositiveBenzinga•Dec 9, 2025, 03:36 PM•Also:
Truist Securities Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $48
📈 PositiveBenzinga•Nov 7, 2025, 03:50 PM
Correction: HC Wainwright & Co. Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $46 (Rating change from Action List to Maintain Buy)
📈 PositiveBenzinga•Nov 7, 2025, 01:13 PM
HC Wainwright & Co. Maintains Action List Buy on Collegium Pharmaceutical, Raises Price Target to $46
📈 PositiveBenzinga•Nov 7, 2025, 11:41 AM
Collegium Pharmaceutical shares are trading higher after the company reported better-than-expected Q3 financial results and raised FY2025 revenue outlook.
📈 PositiveBenzinga•Nov 6, 2025, 12:40 PM
Collegium Pharmaceutical Raises FY2025 Sales Guidance from $745.000M-$760.000M to $775.000M-$785.000M vs $751.631M Est
📈 PositiveBenzinga•Nov 6, 2025, 12:37 PM
Collegium Pharmaceutical Q3 Adj. EPS $2.25 Beats $2.04 Estimate, Sales $209.361M Beat $189.118M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:36 PM
Needham Reiterates Buy on Collegium Pharmaceutical, Maintains $46 Price Target
📈 PositiveBenzinga•Oct 28, 2025, 09:34 AM
Zevra Therapeutics rises amid takeover speculation
📈 PositiveSeeking Alpha•Sep 25, 2025, 02:37 PM•Also:
Frequently Asked Questions about COLL
What is COLL's current stock price?
Collegium Pharmaceutical, Inc. (COLL) is currently trading at $48.88 per share. The stock has moved -0.91% today.
What is the analyst price target for COLL?
The average analyst price target for COLL is $58.00, based on 1 analyst.
What sector is Collegium Pharmaceutical, Inc. in?
Collegium Pharmaceutical, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is COLL's market cap?
Collegium Pharmaceutical, Inc. has a market capitalization of $1.55 billion, making it a small-cap company.
Does COLL pay dividends?
No, Collegium Pharmaceutical, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMPH
Amphastar Pharmaceuticals, Inc.
$26.60
Mkt Cap: $1.2B
ATAI
Atai Beckley N.V
$3.96
Mkt Cap: $0.7B
CRON
Cronos Group Inc.
$2.96
Mkt Cap: $1.1B
DVAX
Dynavax Technologies Corporation
$10.86
Mkt Cap: $1.3B
GDRX
GoodRx Holdings, Inc.
$2.77
Mkt Cap: $0.9B
INVA
Innoviva, Inc.
$19.99
Mkt Cap: $1.3B
MDXG
MiMedx Group, Inc.
$7.05
Mkt Cap: $1.0B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
PCRX
Pacira BioSciences, Inc.
$26.35
Mkt Cap: $1.2B
PLSE
Pulse Biosciences, Inc.
$15.26
Mkt Cap: $1.0B
Explore stocks similar to COLL for comparison